

California State Board of Pharmacy

2720 Gateway Oaks Drive, Suite 100

Sacramento, CA 95833

Phone: (916) 518-3100 Fax: (916) 574-8618

www.pharmacy.ca.gov

Business, Consumer Services and Housing Agency Department of Consumer Affairs Gavin Newsom, Governor



DRAFT LICENSING COMMITTEE MEETING MINUTES

DATE: November 5, 2019

LOCATION: Department of Consumer Affairs

First Floor Hearing Room 1625 North Market Blvd. Sacramento, CA 95834

BOARD MEMBERS PRESENT: Deborah Veale, Licensee Member, Chair

Albert Wong, Licensee Member Allen Schaad, Licensee Member

BOARD MEMBERS NOT PRESENT: Lavanza Butler, Licensee Member, Vice Chair

STAFF PRESENT: Anne Sodergren, Interim Executive Officer

Laura Freedman, DCA Staff Counsel Norine Marks, DCA Staff Counsel

1. Call to Order, Establishment of Quorum, and General Announcements

Chairperson Veale called the meeting to order at 12:30pm.

Committee members present: Albert Wong, Deborah Veale, and Allen Schaad.

2. Public Comment for Items Not on the Agenda, Matters for Future Meetings

No public comments received.

3. Discussion and Consideration of Draft Collaborative Practice Agreement: Pharmacist Protocol for Management of Opioid Use Disorders

Chairperson Veale reported as part of its May 2019 meeting, the committee received a presentation from Dr. James Gaspar and Dr. Talia Puzantian providing an overview of Medication Assisted Treatment (MAT) and current gaps in treatment access. As part of the presentation Dr. Gasper described how DATA 2000 waivers for prescribers has expanded access to treatment outside of OTPs by enabling qualified practitioners to provide buprenorphine. The waiver is underutilized as many professionals that have the authority to use the waiver are not either using their waiver or using the waiver far below its capacity. Dr. Gaspar further described pharmacists' role in community pharmacies and emphasized that pharmacists can make or break someone's MAT.

Following that meeting, the board identified a three-pronged solution intended to address this current treatment gap, including directing the Licensing Committee to develop a sample Collaborative Practice Agreement (CPA) pharmacist could use in collaboration with a practitioner that has received a DATA 200 waiver.

Chairperson Veale reported Dr. Gasper provided a draft CPA that he prepared with Dr. Puzantian for the committee's review and discussion at this meeting.

Dr. Gasper expressed his gratitude for the opportunity to prepare this document for the committee to review. He mentioned in developing the CPA he tried to keep the CPA simple as well as cover all the services for treating opioid addiction. In addition, he reached out to about six other clinical pharmacists that work specifically with opioid use disorder for their feedback. The draft CPA covers buprenorphine as well as naltrexone. The draft CPA lists the need to collaborate with the DATA 2000 waiver only for the buprenorphine component. In addition, he reported the CPA provides the statutory authority, provides referral criteria, identifies the pharmacist's authorized functions under the protocol, provides the requirement for the pharmacist to document appropriate in the health record, and provides the appropriate reference for Substance Abuse and Mental Health Services Administration as well as requires the physician and pharmacist signature.

Chairperson Veale thanked Dr. Gasper for his work on the draft CPA. She expressed concern in section five under "Documentation" where it stated, "The pharmacist's assessment, clinical findings, and plan of care will be documented in an electronic health record mutually accessible by the referring provider and/or primary care physician". The pharmacist may not have access to the "electronic" record. She recommended removing the word "electronic" in this section. The importance is the treatment is documented in the record.

Member Albert Wong commented on the importance of MAT treatment and treatment being more accessible to people with addiction and that the board should assist with public outreach in this area.

Committee Recommendation (Motion): Refer to the Communication and Public Education Committee to develop resources identifying treatment options and location services that pharmacies can provide or post around MAT.

M/S: Wong/Schaad

Support: 3 Oppose: 0 Abstain: 0

Committee Recommendation (Motion): Direct staff to work with counsel to address any minor issues with the language, to ensure it aligns with the board's laws and regulations, and to move forward with the drafted collaborative practice agreement with the removal of the word "electronic" in reference to health records.

M/S: Schaad/Wong

Support: 3 Oppose: 0 Abstain: 0

4. Approval of September 25, 2019, Licensing Committee Meeting Minutes

Committee Recommendation: Approve the draft meeting minutes from the September 25, 2019 as written.

M/S: Wong/Schaad

Support: 3 Oppose: 0 Abstain: 0

5. Review of Licensing Statistics

Chairperson Veale reported on the Licensing statistics for July 1, 2019 through September 30, 2019.

As of September 30, 2019, the board has received 4,132 initial applications, including:

- 1,425 intern pharmacists
- 340 pharmacist exam applications
- 60 advanced practice pharmacists
- 1,277 pharmacy technicians
- 110 community pharmacy license applications
- 43 sterile compounding pharmacy license applications
- 28 nonresident pharmacy license applications
- 8 hospital pharmacy license applications
- 148 automated drug delivery system applications

As of September 30, 2019, the board has received 129 requests for <u>temporary</u> site license applications, including:

- 63 community pharmacy license applications
- 16 sterile compounding pharmacy license applications
- 16 nonresident pharmacy license applications
- 7 hospital pharmacy license applications

As of September 30, 2019, the board has issued 4,168 licenses, renewed 16,336 licenses and has 140,727 active licenses, including:

- 7,700 intern pharmacists
- 47,023 pharmacists
- 574 advanced practice pharmacists
- 70,150 pharmacy technicians
- 6,572 community pharmacies
- 468 hospital pharmacies
- 795 automated drug delivery systems

Chairperson Veale reported on the general application and deficiency processing times and expressed her appreciation to the staff for their hard work in reducing the processing times. She specifically identified the pharmacy deficiency mail processing times have significantly improved since the September 25 committee meeting, as shown in the comparison chart.

Chairperson Veale stated to reduce processing times board staff worked overtime and others were redirected to assisted with some functions.

Premises Application Types	Application Processing Times as of 9/18/2019	Application Processing Times as of 10/22/2019	Deficiency Mail Processing Times as of 9/18/2019	Deficiency Mail Processing Times as of 10/22/2019
Pharmacy	30	29	107	25
Nonresident Pharmacy	30	33	103	15
Sterile Compounding	33	22	79	33
Nonresident Sterile Compounding	30	5	Current	14
Outsourcing	Current	Current	Current	Current
Nonresident Outsourcing	20	Current	Current	Current
Hospital Satellite Compounding Pharmacy	Current	Current	Current	Current
Hospital	28	6	30	20
Clinic	33	21	58	22
Wholesaler	37	Current	46	20
Nonresident Wholesaler	43	32	56	20
Third-Party Logistics Provider	10	Current	35	Current
Nonresident Third- Party Logistics Provider	29	19	35	12
Automated Drug Delivery System	N/A	Current	N/A	Current
Automated Patient Dispensing System	N/A	Current	N/A	Current
Emergency Medical Services Automated Drug Delivery System	N/A	Current	N/A	Current

Individual Application Type	Application Processing Times as of 9/18/2019	Application Processing Times as of 10/22/2019	Deficiency Mail Processing Times as of 9/18/2019	Deficiency Mail Processing Times as of 10/22/2019
Exam Pharmacist	25	34	45	11
Pharmacist Initial Licensure	9	4	Current	Current
Advanced Practice Pharmacist	50	28	15	22
Intern Pharmacist	46	8	30	Current
Pharmacy Technician	34	33	10	7
Designated Representative	44	33	58	20
Designated Represenatives-3PL	42	33	Current	15
Designated Representatives- Reverse Distributor	Current	Current	Current	Current

Member Albert Wong requested the board to breakdown in the licensing stats the number of chain pharmacy applications received and number of chain pharmacies that have closed.

6. Future Committee Meeting Dates

The next Licensing Committee meetings is currently scheduled to meet during the next Board meeting in January and May 2020. Chairperson Veale anticipates another licensing committee meeting scheduled soon to discuss the Advanced Pharmacy Technician.

Chairperson Veale adjourned the meeting at 1:07 p.m.